Next 10 |
home / stock / srrk / srrk articles
Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key pr...
U.S. stocks were lower, with the Dow Jones index falling more than 200 points on Tuesday. Shares of NIO Inc. (NYSE: NIO) rose during Tuesday&rsquo...
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with...
Samsara BioCapital GP LLC, 10% Owner at Scholar Rock Holding (NASDAQ:SRRK), reported a large insider buy on October 18, according to a new SEC fili...
Srinivas Akkaraju, Board Member at Scholar Rock Holding (NASDAQ:SRRK), reported a large insider buy on October 18, according to a new SEC filing. ...
Although U.S. stocks closed higher on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence...
Gainers OpGen, Inc. (NASDAQ: OPGN) jumped 593% to $2.33 following two SEC filings from the precision medicine company. The company has received a...
U.S. stocks traded mixed, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s sessi...
Gainers Applied UV, Inc. (NASDAQ: AUVI) gained 60.4% to $0.4924. Applied UV said its new product, the Airocide® Pro+ air purification system f...
News, Short Squeeze, Breakout and More Instantly...
Scholar Rock Holding Corporation Company Name:
SRRK Stock Symbol:
NASDAQ Market:
Scholar Rock Holding Corporation Website:
2024-06-13 08:00:15 ET Etzer Darout from BMO Capital issued a price target of $31.00 for SRRK on 2024-06-13 07:24:00. The adjusted price target was set to $31.00. At the time of the announcement, SRRK was trading at $9.39. The overall price target consensus is at $28.50 ...
Promising objective response rates (ORR) were observed in multiple tumor types in anti-PD-(L)1 resistant patients Analysis of baseline biomarker data in clear cell renal cell carcinoma (ccRCC) patients reveals a doubling of the ORR highlighting a potential patient selection strategy ...
- Updated safety and efficacy results on SRK-181 will be featured in an oral presentation on Monday, June 3 rd , at 1:50 p.m CDT/2:50 p.m. EDT - Company will host conference call to discuss the data on Tuesday, June 4 th at 7:00 a.m. CDT/8:00 a.m. EDT Scholar Rock (NASDA...